Company profile
Nutra Pharma Corp.
OTC: NPHC · Healthcare · Drug Manufacturers - Specialty & Generic
#982 of 1,418 Healthcare companies by revenue48th-percentile growth
EA Score
30DFH 17DQ 44GM 34SS 44
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ filing timeliness, balance-sheet leverage
Methodology →Revenue TTM
$207.0k
Rev growth YoY (TTM)
-42.2%
Net income (FY)
-$2.0M
Employees
6
as of 2026-08-25
Market cap
$716.0k
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$257.6k$257.6k2025
Net income-$2.0M-$2.0M2025
Operating income-$1.5M-$1.5M2025
Total assets$584.6k$584.6k2025
Liabilities$17.4M$17.4M2025
Equity-$16.8M-$16.8M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nutra Pharma Corp.’s revenue?
Nutra Pharma Corp. booked $257.6k in FY2025 revenue, growing 4.6% year over year — about the middle of the pack among Healthcare companies we track, at a -794.8% net margin.
Peers · Healthcare
Abattis Bioceuticals Corp.——Entia Biosciences, Inc.——CEL-SCI Corporation32DNewCardio, Inc.——Savara Inc.50DNexteligent Holdings, Inc.46DNeighbors
Broward →Key facts
CEOMichael D. Flax
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPlantation, FL
ExchangeOTC: NPHC
Employees6
IPO date2001-12-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.